#USA #New York #Gross Law Firm #Neumora Therapeutics #NMRA

Neumora Therapeutics, Inc. Shareholder Alert

Investors who hold shares in Neumora Therapeutics, Inc. (NASDAQ: NMRA) have an important deadline approaching. The Gross Law Firm has issued a notice specifically aimed at shareholders, urging them to take action before April 7, 2025. This notice provides critical information regarding potential rights and avenues for recourse for those who purchased shares during a specific class period, which commenced around September 15, 2023.

Class Action Lawsuit Overview

The Gross Law Firm is representing a class of individuals and entities that acquired Neumora's common stock, potentially impacted by inaccurate disclosures made by the company during the class period. The lawsuit centers on allegations that the defendants failed to disclose key information and made materially misleading statements regarding Neumora's Phase Three clinical program.

The complaint claims that initial trials were not conducted on an adequately representative patient population, particularly regarding gender ratios, which compromises the reliability of outcomes. Furthermore, adjustments made to the inclusion criteria for specific patient demographics further complicate Neumora's ability to claim robust efficacy from their leading therapeutic candidate, Navacaprant, which focuses on treating moderate to severe Major Depressive Disorder (MDD).

Important Actions for Investors

Shareholders who are interested in pursuing action through the class action lawsuit are encouraged to register through the Gross Law Firm. It's important to note that registering does not obligate individuals to act as lead plaintiff, although they may choose to do so. All registered investors will gain access to a portfolio monitoring tool that will provide updates on the ongoing case's progression.

This is a critical time for shareholders to evaluate their options. The impending deadline offers investors a chance to reclaim some of their potential losses borne from misleading corporate communication practices. It is essential to act swiftly, as the April 7, 2025 deadline is fast approaching.

Why Choose Gross Law Firm?

The Gross Law Firm is renowned for its dedication to protecting investors' rights, specializing in class-action litigation. Their commitment lies in ensuring businesses adhere to ethical practices and legal standards, all while striving for recovery on behalf of harmed investors. Historical outcomes have positioned the firm as a trusted advocate in the landscape of financial and securities law, urging shareholders who suspect wrongdoing to come forward and stand against corporate misconduct.

Interested parties can directly contact The Gross Law Firm at their New York office or through their website for more information and guidance on the process.

As the deadline approaches, shareholders should not delay in reaching out to discuss their rights and possible legal actions regarding their Neumora holdings. With the backdrop of a complex legal situation, qualified legal counsel can make a significant difference in navigating these turbulent waters.

Contact Information

For inquiries, shareholders can reach The Gross Law Firm:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Conclusion

As investors monitor the evolving landscape of Neumora Therapeutics and its forthcoming clinical developments, it’s also crucial for affected shareholders to safeguard their investments by staying informed and engaged with their legal rights. The Gross Law Firm stands by to assist and guide them in this multifaceted legal context, heralding a cautious yet proactive approach for those impacted by this situation.